PMID: 8597355Dec 29, 1995Paper

Prevention and treatment of graft-versus-host disease

Annals of the New York Academy of Sciences
N J Chao, P G Schlegel

Abstract

Graft-versus-host disease remains a formidable barrier in allogeneic bone marrow transplantation. Studies have shown that effective prophylaxis results in improved overall survival for patients following allogeneic bone marrow transplantation. Various methods to prevent GVHD have been devised over the years including drug therapy, monoclonal antibodies, and T-cell depletion. Many of these prophylaxis regimens have been successful in improving the outcome in patients, with some regimens resulting in only a 9% incidence of acute GVHD in selected patients. Yet, GVHD remains an important problem for those patients in whom prophylaxis fails. Therapy for GVHD has relied on drugs and monoclonal antibodies, and the results of therapy for severe GVHD have been unsatisfactory. As immunologic understanding of the afferent and efferent phases of GVHD continues to be elucidated, more targeted therapy will be introduced and hopefully will result in better outcomes.

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Annals of the New York Academy of Sciences
J L Ferrara
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
K TeranishiD K Cooper
Annals of the New York Academy of Sciences
H GrouxM G Roncarolo
© 2021 Meta ULC. All rights reserved